Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial

Delafloxacin is a novel fluoroquinolone with activity against Gram-positive, Gram-negative, and atypical pathogens, including fluoroquinolone-nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA). The microbiological results of a phase 3 clinical trial in adults with community-acquired p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: McCurdy, Sandra, Keedy, Kara, Lawrence, Laura, Nenninger, Ashley, Sheets, Amanda, Quintas, Megan, Cammarata, Sue
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2020
Matèries:
Clinical Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7038307/
https://ncbi.nlm.nih.gov/pubmed/31844013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01949-19
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars